Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Daiichi Sankyo and Merck ink ADC codevelopment deal

by Rick Mullin
October 30, 2023 | A version of this story appeared in Volume 101, Issue 36

 

Daiichi Sankyo and Merck & Co. have signed a commercialization agreement for three of Daiichi Sankyo’s antibody-drug conjugate (ADC) candidates. The three ADCs—patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan—are in various stages of clinical development for the treatment of multiple solid tumors as monotherapies or in combination with other treatments. The partners would jointly commercialize resulting therapies worldwide, except in Japan, where Daiichi Sankyo would be solely responsible for manufacture and supply. Merck will pay Daiichi $4 billion up front under terms of the agreement.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.